Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
How to buy shares in Bolt Biotherapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BOLT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Bolt Biotherapeutics stock price (NASDAQ: BOLT)Use our graph to track the performance of BOLT stocks over time.
Bolt Biotherapeutics shares at a glance
|Latest market close||$17.51|
|52-week range||$11.20 - $43.07|
|50-day moving average||$14.88|
|200-day moving average||$23.21|
|Wall St. target price||$39.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Bolt Biotherapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Bolt Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bolt Biotherapeutics price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||14.15%|
|3 months (2021-05-03)||-28.91%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Bolt Biotherapeutics financials
|Gross profit TTM||$-40,126,000|
|Return on assets TTM||-18.73%|
|Return on equity TTM||-45.71%|
|Market capitalisation||$446.6 million|
TTM: trailing 12 months
Shorting Bolt Biotherapeutics shares
There are currently 1.8 million Bolt Biotherapeutics shares held short by investors – that's known as Bolt Biotherapeutics's "short interest". This figure is 4.7% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Bolt Biotherapeutics shares can be evaluated.
Bolt Biotherapeutics's "short interest ratio" (SIR)
Bolt Biotherapeutics's "short interest ratio" (SIR) is the quantity of Bolt Biotherapeutics shares currently shorted divided by the average quantity of Bolt Biotherapeutics shares traded daily (recently around 199177.04918033). Bolt Biotherapeutics's SIR currently stands at 9.15. In other words for every 100,000 Bolt Biotherapeutics shares traded daily on the market, roughly 9150 shares are currently held short.
To gain some more context, you can compare Bolt Biotherapeutics's short interest ratio against those of similar companies.
However Bolt Biotherapeutics's short interest can also be evaluated against the total number of Bolt Biotherapeutics shares, or, against the total number of tradable Bolt Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bolt Biotherapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Bolt Biotherapeutics shares in existence, roughly 50 shares are currently held short) or 0.1091% of the tradable shares (for every 100,000 tradable Bolt Biotherapeutics shares, roughly 109 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Bolt Biotherapeutics.
Find out more about how you can short Bolt Biotherapeutics stock.
Bolt Biotherapeutics share dividends
We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.
Bolt Biotherapeutics overview
Bolt Biotherapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Stocks similar to Bolt Biotherapeutics
Bolt Biotherapeutics in the news
European Uber Rival Firm Reaches $4.8B Valuation Following Fundraise For Grocery-Delivery Service: Report
Bolt valued at $4.75 billion as Uber rival aims to push into on-demand grocery delivery
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Frequently asked questionsWhat percentage of Bolt Biotherapeutics is owned by insiders or institutions?
Currently 3.626% of Bolt Biotherapeutics shares are held by insiders and 87.049% by institutions. How many people work for Bolt Biotherapeutics?
Latest data suggests 65 work at Bolt Biotherapeutics. When does the fiscal year end for Bolt Biotherapeutics?
Bolt Biotherapeutics's fiscal year ends in December. Where is Bolt Biotherapeutics based?
Bolt Biotherapeutics's address is: 900 Chesapeake Drive, Redwood City, CA, United States, 94063
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert